Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
暂无分享,去创建一个
Elly van Riet | Wim Jiskoot | W. Jiskoot | J. Bouwstra | Suzanne M Bal | Zhi Ding | Joke A Bouwstra | S. Bal | E. van Riet | Z. Ding | Zhi Ding
[1] J. Bouwstra,et al. Quantitative assessment of the transport of elastic and rigid vesicle components and a model drug from these vesicle formulations into human skin in vivo. , 2004, The Journal of investigative dermatology.
[2] R. Langer,et al. Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. , 1997, Biomaterials.
[3] Mark R Prausnitz,et al. Coated microneedles for transdermal delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[4] S. Edgar,et al. CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. , 2007, International immunology.
[5] H. Ueno,et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. , 2008, Immunity.
[6] A. Banga,et al. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. , 2009, International journal of pharmaceutics.
[7] R. Rappuoli,et al. Transcutaneous Immunization with Cross-Reacting Material CRM197 of Diphtheria Toxin Boosts Functional Antibody Levels in Mice Primed Parenterally with Adsorbed Diphtheria Toxoid Vaccine , 2008, Infection and Immunity.
[8] C. Caux,et al. Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria1 , 2006, The Journal of Immunology.
[9] M. Kapsenberg,et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. , 2007, The Journal of investigative dermatology.
[10] G. Cevc,et al. Transdermal immunization with large proteins by means of ultradeformable drug carriers , 1995, European journal of immunology.
[11] P. Brennan,et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. , 1995, Science.
[12] J. Bouwstra,et al. Structure of the skin barrier and its modulation by vesicular formulations. , 2003, Progress in lipid research.
[13] R. Rappuoli,et al. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. , 2003, The Journal of infectious diseases.
[14] V. Kuchroo,et al. IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells , 2008, Nature Immunology.
[15] Diane E. Sutter,et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery , 2002, Nature Medicine.
[16] J. Cross,et al. Topical resiquimod promotes priming of CTL to parenteral antigens. , 2009, Vaccine.
[17] T. Geijtenbeek,et al. Two way communication between neutrophils and dendritic cells. , 2006, Current opinion in pharmacology.
[18] T. Prow,et al. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. , 2010, Biomaterials.
[19] D. Schmitt,et al. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). , 2003, Vaccine.
[20] M. Alter,et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. , 1990, Archives of internal medicine.
[21] L. Payne,et al. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments , 2008, Human vaccines.
[22] H. Spits,et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.
[23] W. Jiskoot,et al. Immune Modulation by Adjuvants Combined with Diphtheria Toxoid Administered Topically in BALB/c Mice After Microneedle Array Pretreatment , 2009, Pharmaceutical Research.
[24] N. Lycke,et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. , 1997, Journal of immunology.
[25] Sanyog Jain,et al. Mannosylated niosomes as carrier adjuvant system for topical immunization , 2005, The Journal of pharmacy and pharmacology.
[26] Leaf Huang,et al. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. , 2007, Molecular immunology.
[27] S. Muller,et al. Immunization onto bare skin with heat‐labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge , 2001, Immunology.
[28] R. Lavker,et al. Safety and Immunogenicity of an Enterotoxigenic Escherichia coli Vaccine Patch Containing Heat-Labile Toxin: Use of Skin Pretreatment To Disrupt the Stratum Corneum , 2007, Infection and Immunity.
[29] Petras Juzenas,et al. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[30] W. Jiskoot,et al. Microneedle-Based Transcutaneous Immunisation in Mice with N-Trimethyl Chitosan Adjuvanted Diphtheria Toxoid Formulations , 2010, Pharmaceutical Research.
[31] M. Schmuth,et al. Expression of the C‐C chemokine MIP‐3α/CCL20 in human epidermis with impaired permeability barrier function , 2002, Experimental dermatology.
[32] S W Hui,et al. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. , 2006, Vaccine.
[33] K. Dubin,et al. Physical disruption of skin during poxvirus immunization is critical for the generation of highly protective T cell-mediated immunity , 2010, Nature Medicine.
[34] B. Autran,et al. Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans. , 2010, The Journal of clinical investigation.
[35] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[36] C. Cooper,et al. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.
[37] G. Matyas,et al. Skin immunization made possible by cholera toxin , 1998, Nature.
[38] T. Jakob,et al. Bacterial DNA and CpG–Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL–12 Production: Implications for the Augmentation of Th1 Responses , 1999, International Archives of Allergy and Immunology.
[39] J. Matriano,et al. Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.
[40] J. Hooper,et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge , 2006, Vaccine.
[41] Y. Maa,et al. Adjuvantation of epidermal powder immunization. , 2001, Vaccine.
[42] Mark R Prausnitz,et al. Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles , 2008, Advanced materials.
[43] Samir Mitragotri,et al. Micro-scale devices for transdermal drug delivery. , 2008, International journal of pharmaceutics.
[44] J. Banchereau,et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. , 1998, Journal of immunology.
[45] R. Kennedy,et al. Smallpox and Vaccinia , 1999 .
[46] Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.
[47] A. Hickey,et al. Pulmonary vaccine delivery , 2007, Expert review of vaccines.
[48] J. Oxford,et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. , 2009, Vaccine.
[49] G. Belz,et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. , 2003, Blood.
[50] C. Czerkinsky,et al. Transcutaneous Immunization with Cholera Toxin B Subunit Adjuvant Suppresses IgE Antibody Responses Via Selective Induction of Th1 Immune Responses 1 , 2003, The Journal of Immunology.
[51] P. Laurent,et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. , 2007, Vaccine.
[52] N. Lycke. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1‐DD/ISCOM , 2004, Cellular microbiology.
[53] P. Crooks,et al. Flux Across of Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol In Vitro , 2008, Pharmaceutical Research.
[54] M. Prausnitz,et al. Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage , 2010, Pharmaceutical Research.
[55] V E Schijns,et al. Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.
[56] Ryan F. Donnelly,et al. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety , 2010, Drug delivery.
[57] Zhu Guo,et al. Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice , 2007, Clinical and Vaccine Immunology.
[58] P. Elias,et al. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. , 1992, The Journal of clinical investigation.
[59] M. Kapsenberg. Dendritic-cell control of pathogen-driven T-cell polarization , 2003, Nature Reviews Immunology.
[60] H. Benson. Transfersomes for transdermal drug delivery , 2006, Expert opinion on drug delivery.
[61] Robert Langer,et al. Transdermal drug delivery , 2008, Nature Biotechnology.
[62] W. Jiskoot,et al. Rational design of nasal vaccines , 2008, Journal of drug targeting.
[63] R. Clark,et al. The Vast Majority of CLA+ T Cells Are Resident in Normal Skin1 , 2006, The Journal of Immunology.
[64] S. Saeland,et al. Cutaneous dendritic cells. , 2005, Seminars in immunology.
[65] Dexiang Chen,et al. Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses , 2001, Journal of Virology.
[66] G. Núñez,et al. Peptidoglycan Signaling in Innate Immunity and Inflammatory Disease* , 2005, Journal of Biological Chemistry.
[67] T. Geijtenbeek,et al. Self- and nonself-recognition by C-type lectins on dendritic cells. , 2004, Annual review of immunology.
[68] E. Spaun,et al. The influence of epidermal thickness on transcutaneous oxygen pressure measurements in normal persons. , 1988, Scandinavian journal of clinical and laboratory investigation.
[69] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[70] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[71] J. Ting,et al. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. , 2005, Annual review of immunology.
[72] A. Brooks,et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.
[73] F. Sallusto,et al. Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity , 2009, European journal of immunology.
[74] J. Pitcovski,et al. B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. , 2006, Veterinary immunology and immunopathology.
[75] Mark R Prausnitz,et al. Precise microinjection into skin using hollow microneedles. , 2006, The Journal of investigative dermatology.
[76] J. Yoshimitsu,et al. Self-dissolving microneedles for the percutaneous absorption of EPO in mice , 2006, Journal of drug targeting.
[77] F. Watt. Terminal differentiation of epidermal keratinocytes. , 1989, Current opinion in cell biology.
[78] Mark R. Prausnitz,et al. Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.
[79] B. Narasimhan,et al. Vaccine adjuvants: current challenges and future approaches. , 2009, Journal of pharmaceutical sciences.
[80] F. Martinon,et al. NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.
[81] L. Babiuk,et al. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[82] C. Katlama,et al. Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial , 2010, PloS one.
[83] E. Menzel,et al. Two-dimensional elastic properties of human skin in terms of an incremental model at the in vivo configuration. , 1995, Medical engineering & physics.
[84] J. Bos,et al. Skin immune system. , 1990, Cancer treatment and research.
[85] J. Banchereau,et al. Pyogenic Bacterial Infections in Humans with MyD88 Deficiency , 2003, Science.
[86] Frank O. Nestle,et al. Skin immune sentinels in health and disease , 2009, Nature Reviews Immunology.
[87] C. Alving,et al. Principles of transcutaneous immunization using cholera toxin as an adjuvant. , 1999, Vaccine.
[88] J. Bouwstra,et al. Skin Penetration and Mechanisms of Action in the Delivery of the D2-Agonist Rotigotine from Surfactant-Based Elastic Vesicle Formulations , 2003, Pharmaceutical Research.
[89] S. Muller,et al. Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy , 2005, Cellular and Molecular Life Sciences CMLS.
[90] G. Heller,et al. Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells1 , 2004, The Journal of Immunology.
[91] P. Kaye,et al. Dendritic cells at the host-pathogen interface , 2002, Nature Immunology.
[92] T. Kupper,et al. Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.
[93] Michael S Roberts,et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[94] R. Tan,et al. Optimization of epicutaneous immunization for the induction of CTL. , 2003, Vaccine.
[95] R. Zinkernagel,et al. The influence of antigen organization on B cell responsiveness. , 1993, Science.
[96] R. Gupta,et al. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. , 1994, Biologicals : journal of the International Association of Biological Standardization.
[97] H. Ueno,et al. Harnessing Human Dendritic Cell Subsets to Design Novel Vaccines , 2009, Annals of the New York Academy of Sciences.
[98] C. Thompson,et al. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.
[99] M. Prausnitz,et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine , 2010, Gene Therapy.
[100] J. Bouwstra,et al. Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[101] E. Sandström,et al. Strong HIV-Specific CD4+ and CD8+ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes , 2010, Clinical and Vaccine Immunology.
[102] G. Ada. Overview of vaccines. , 1996, Methods in molecular medicine.
[103] G. Glenn,et al. Dose sparing with intradermal injection of influenza vaccine. , 2004, The New England journal of medicine.
[104] Adrian C. Williams,et al. Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.
[105] Y. Maa,et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. , 2003, Vaccine.
[106] R. Rappuoli,et al. The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.
[107] Adrian C. Williams,et al. Skin Delivery of Oestradiol from Deformable and Traditiona Liposomes: Mechanistic Studies , 1999, The Journal of pharmacy and pharmacology.
[108] J. Bos,et al. The 500 Dalton rule for the skin penetration of chemical compounds and drugs , 2000, Experimental dermatology.
[109] J. Haynes,et al. Epidermal DNA vaccine for influenza is immunogenic in humans. , 2006, Vaccine.
[110] R. Coffman,et al. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.
[111] K. Hogquist,et al. Identification of a novel population of Langerin+ dendritic cells , 2007, The Journal of experimental medicine.
[112] Mark R Prausnitz,et al. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. , 2004, Journal of biomechanics.
[113] P. Friedmann,et al. Disappearance of epidermal Langerhans cells during PUVA therapy , 1981, The British journal of dermatology.
[114] J. Ring,et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. , 2003, The Journal of investigative dermatology.
[115] J. Bos,et al. Cutting Edge: Loss of TLR2, TLR4, and TLR5 on Langerhans Cells Abolishes Bacterial Recognition1 , 2007, The Journal of Immunology.
[116] G. Kelsoe. Studies of the humoral immune response , 2000, Immunologic research.
[117] Mark R Prausnitz,et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[118] D. Liepmann,et al. In vivo evaluation of a microneedle-based miniature syringe for intradermal drug delivery , 2009, Biomedical microdevices.
[119] Kanji Takada,et al. Feasibility of microneedles for percutaneous absorption of insulin. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[120] Wijaya Martanto,et al. Microinfusion Using Hollow Microneedles , 2006, Pharmaceutical Research.
[121] Johann W Wiechers,et al. Water distribution and related morphology in human stratum corneum at different hydration levels. , 2003, The Journal of investigative dermatology.
[122] M. Tafaghodi,et al. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[123] Samir Mitragotri,et al. Immunization without needles , 2005, Nature Reviews Immunology.
[124] K. Mills,et al. Manipulating the immune system: humoral versus cell-mediated immunity. , 2001, Advanced drug delivery reviews.
[125] R. Clark. Skin-resident T cells: the ups and downs of on site immunity. , 2010, The Journal of investigative dermatology.
[126] W. Heath,et al. Dendritic cell subsets in primary and secondary T cell responses at body surfaces , 2009, Nature Immunology.
[127] N. K. Jain,et al. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[128] Conor O'Mahony,et al. Processing difficulties and instability of carbohydrate microneedle arrays , 2009, Drug development and industrial pharmacy.
[129] Y. Aramaki,et al. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. , 2007, Vaccine.
[130] R. Pal,et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. , 2008, Biochemical and biophysical research communications.
[131] R. Vabulas,et al. Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments , 2002, European journal of immunology.
[132] J. Shiver,et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex , 2006, Proceedings of the National Academy of Sciences.
[133] A. Fahr,et al. Skin penetration enhancement by a microneedle device (Dermaroller) in vitro: dependency on needle size and applied formulation. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[134] A. Rudensky,et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.
[135] R. Haut. Biomechanics of Soft Tissue , 2002 .
[136] G. Leroux-Roels,et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.
[137] H. Schaefer,et al. Principles of Percutaneous Absorption , 1980 .
[138] M. Cormier,et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. , 2006, Vaccine.
[139] W. Hennink,et al. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[140] B. Malissen,et al. Langerhans cells--revisiting the paradigm using genetically engineered mice. , 2006, Trends in immunology.
[141] A. Shaw,et al. Triggering TLR signaling in vaccination. , 2006, Trends in immunology.
[142] T. D. Connell,et al. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by Type I and Type II heat-labile enterotoxins , 2007, Expert review of vaccines.
[143] K. Porter,et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. , 2003, Virology.
[144] Koichiro Nakamura,et al. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. , 2004, The Journal of investigative dermatology.
[145] Mark R. Prausnitz,et al. Coating Formulations for Microneedles , 2007, Pharmaceutical Research.
[146] J. Bouwstra,et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[147] C. Janeway,et al. Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.
[148] G. Cevc,et al. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.
[149] H. Schild,et al. Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.
[150] Massimo Gadina,et al. Cytokines and Transcription Factors That Regulate T Helper Cell Differentiation: New Players and New Insights , 2003, Journal of Clinical Immunology.
[151] Ruslan Medzhitov,et al. Toll-like receptors and innate immunity , 2001, Nature Reviews Immunology.
[152] F. Hirahara,et al. Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. , 2005, Viral immunology.
[153] L. Miller,et al. Toll-like receptors in the skin , 2007, Seminars in Immunopathology.
[154] B. Malissen,et al. Priming of CD8+ and CD4+ T Cells in Experimental Leishmaniasis Is Initiated by Different Dendritic Cell Subtypes1 , 2009, The Journal of Immunology.
[155] J. Dutz,et al. Topical TLR9 agonists induce more efficient cross‐presentation of injected protein antigen than parenteral TLR9 agonists do , 2007, European journal of immunology.
[156] C. Alving,et al. Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.
[157] J. Davoust,et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. , 2000, Immunity.
[158] K. Tamaki,et al. Role of Langerhans cells in cutaneous protective immunity: is the reappraisal necessary? , 2006, Journal of dermatological science.
[159] T. Ganz,et al. TGF-α Regulates TLR Expression and Function on Epidermal Keratinocytes1 , 2005, The Journal of Immunology.
[160] N. Mickuvienė,et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial , 2009, BMC Medicine.
[161] R. Zeuner,et al. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. , 2003, Trends in immunology.
[162] Dinesh Mishra,et al. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. , 2006, Vaccine.
[163] P. Ricciardi-Castagnoli,et al. CpG motifs induce Langerhans cell migration in vivo. , 2000, International immunology.
[164] Göran Stemme,et al. Side-opened out-of-plane microneedles for microfluidic transdermal liquid transfer , 2003 .
[165] C. Janeway,et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.
[166] Toll-free immunity? , 2008, Nature Medicine.
[167] Jung-Hwan Park,et al. Dissolving microneedles for transdermal drug delivery. , 2008, Biomaterials.
[168] M. Prausnitz,et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge , 2009, Proceedings of the National Academy of Sciences.
[169] H. Ueno,et al. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. , 2009, Human immunology.
[170] G. Vandermeulen,et al. Effect of Tape Stripping and Adjuvants on Immune Response After Intradermal DNA Electroporation , 2009, Pharmaceutical Research.
[171] J. Belisle,et al. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. , 2004, The Journal of clinical investigation.
[172] S. Abraham,et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α , 1996, Nature.
[173] E. Devilard,et al. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells , 2007, The Journal of experimental medicine.
[174] Fernand Labrie,et al. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. , 2005, The Journal of investigative dermatology.
[175] R. Haworth,et al. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[176] S. Akira,et al. Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals1 , 2006, The Journal of Immunology.
[177] S. Hoffman,et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. , 2002, Human gene therapy.
[178] W. J. Mulholland,et al. Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization. , 2006, The Journal of investigative dermatology.
[179] M. Allen,et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. , 1998, Journal of pharmaceutical sciences.
[180] G. Matyas,et al. Needle-Free Skin Patch Vaccination Method for Anthrax , 2004, Infection and Immunity.
[181] H. Shimizu,et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. , 2006, Cancer research.
[182] J. Berzofsky,et al. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. , 2004, The Journal of clinical investigation.
[183] F. Sallusto,et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells , 2000, Nature Immunology.
[184] Takaya Miyano,et al. Sugar Micro Needles as Transdermic Drug Delivery System , 2005, Biomedical microdevices.
[185] P. Laurent,et al. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook , 2008, Expert review of vaccines.
[186] J. Bouwstra,et al. Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[187] G. Glenn,et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. , 2007, Vaccine.
[188] Thomas Gebhardt,et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus , 2009, Nature Immunology.
[189] C. Katlama,et al. Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans1 , 2008, The Journal of Immunology.
[190] I. Kimber,et al. Langerhans cells require signals from both tumour necrosis factor‐α and interleukin‐1β for migration , 1997, Immunology.
[191] G. Glenn,et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. , 2005, Vaccine.
[192] W. Jiskoot,et al. Transcutaneous Immunization Studies in Mice Using Diphtheria Toxoid-Loaded Vesicle Formulations and a Microneedle Array , 2010, Pharmaceutical Research.
[193] M. Guan,et al. Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. , 2009, Journal of dermatological science.
[194] Christoph Wilhelm,et al. Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset , 2008, Nature Immunology.
[195] S. Jain,et al. Transfersomes—A Novel Vesicular Carrier for Enhanced Transdermal Delivery: Development, Characterization, and Performance Evaluation , 2003, Drug development and industrial pharmacy.
[196] H. Dupont,et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial , 2008, The Lancet.
[197] W. Jiskoot,et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[198] R. Ward,et al. Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection. , 2007, Vaccine.
[199] R. Compans,et al. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. , 2006, Vaccine.
[200] Y. Maa,et al. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. , 2002, AIDS research and human retroviruses.
[201] F. Ginhoux,et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state , 2007, The Journal of experimental medicine.
[202] L. Turka,et al. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. , 1994, Immunology today.
[203] J. Reimann,et al. Modulation of Gene-Gun-Mediated Th2 Immunity to Hepatitis B Surface Antigen by Bacterial CpG Motifs or IL-12 , 2001, Intervirology.
[204] B. Combadière,et al. Particle-based vaccines for transcutaneous vaccination. , 2008, Comparative immunology, microbiology and infectious diseases.
[205] C. Alving,et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.
[206] J. Banchereau,et al. Influence of the transcription factor RORγt on the development of NKp46+ cell populations in gut and skin , 2009, Nature Immunology.
[207] M. Prausnitz,et al. Improved influenza vaccination in the skin using vaccine coated microneedles. , 2009, Vaccine.
[208] J. Ring,et al. Various members of the Toll‐like receptor family contribute to the innate immune response of human epidermal keratinocytes , 2005, Immunology.
[209] F. Brown,et al. A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. , 2005, Veterinary immunology and immunopathology.
[210] D. Weiner,et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. , 2008, Vaccine.
[211] R. Steinman,et al. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. , 2007, The Journal of clinical investigation.
[212] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[213] R. Stout,et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. , 2000, Vaccine.
[214] D. Duffy,et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. , 2009, The Journal of investigative dermatology.
[215] S. Muller,et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells , 2002, Immunology.
[216] C. Caux,et al. Macrophage Inflammatory Protein 3α Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors , 2000, The Journal of experimental medicine.
[217] Brian W. Barry,et al. Dermatological Formulations: Percutaneous Absorption , 1983 .
[218] H. Junginger,et al. The effect of surfactant-based elastic and rigid vesicles on the penetration of lidocaine across human skin , 2002 .
[219] Michel Cormier,et al. Microneedle-based vaccines. , 2009, Current topics in microbiology and immunology.
[220] S. Mitragotri,et al. Low-frequency ultrasound as a transcutaneous immunization adjuvant. , 2005, Vaccine.
[221] M. Hilleman. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. , 2000, Vaccine.
[222] P. Wollan,et al. Making vaccines more acceptable--methods to prevent and minimize pain and other common adverse events associated with vaccines. , 2001, Vaccine.
[223] J. Connolly,et al. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. , 2006, Blood.
[224] N. Weiner,et al. Transfollicular Drug Delivery , 1995, Pharmaceutical Research.
[225] V. Ward,et al. Transcutaneous vaccination with virus-like particles. , 2006, Vaccine.
[226] J. Pfeilschifter,et al. TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells. , 2007, Molecular immunology.
[227] G. Chang,et al. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. , 2009, The Journal of general virology.
[228] Chandra Sekhar Kolli,et al. Characterization of Solid Maltose Microneedles and their Use for Transdermal Delivery , 2007, Pharmaceutical Research.
[229] D. Mahvi,et al. A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients , 2007, Clinical Cancer Research.
[230] C Caux,et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. , 1997, Blood.
[231] I. Toth,et al. Oral vaccine delivery--new strategies and technologies. , 2009, Current drug delivery.
[232] Elly van Riet,et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[233] M. Prausnitz,et al. Transdermal Influenza Immunization with Vaccine-Coated Microneedle Arrays , 2009, PLoS ONE.
[234] C. Mackay,et al. T Follicular Helper Cells Express a Distinctive Transcriptional Profile, Reflecting Their Role as Non-Th1/Th2 Effector Cells That Provide Help for B Cells1 , 2004, The Journal of Immunology.
[235] D. Jarrossay,et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.
[236] A. Iwasaki,et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection , 2009, The Journal of experimental medicine.
[237] C. Alving,et al. Advances in vaccine delivery: transcutaneous immunisation. , 1999, Expert opinion on investigational drugs.
[238] K. Palmer,et al. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. , 2006, Bioconjugate chemistry.
[239] C. Alving,et al. Transcutaneous immunization: T cell responses and boosting of existing immunity. , 2001, Vaccine.
[240] Mark G. Allen,et al. Polymer Microneedles for Controlled-Release Drug Delivery , 2006, Pharmaceutical Research.
[241] T. Redelmeier,et al. Skin Barrier: Principles of Percutaneous Absorption , 1996 .
[242] G. E. El Maghraby,et al. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. , 2004, International journal of pharmaceutics.
[243] D. Fuller,et al. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. , 2005, Vaccine.
[244] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[245] P. van Damme,et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.
[246] Sanyog Jain,et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. , 2005, International journal of pharmaceutics.
[247] G. Cheng,et al. TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response1 , 2006, The Journal of Immunology.
[248] P. Scheinmann,et al. Vaccine allergy and pseudo-allergy. , 2003, European journal of dermatology : EJD.
[249] Yvonne Perrie,et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.
[250] S. Hoffman,et al. Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[251] G. Lagoumintzis,et al. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. , 2010, International journal of pharmaceutics.
[252] P. Perrin,et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. , 2005, Immunity.
[253] Clare L. Bennett,et al. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions , 2009, Proceedings of the National Academy of Sciences.
[254] D. Busch,et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. , 2008, Vaccine.
[255] G. Glenn,et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch , 2007, Expert review of vaccines.
[256] H. Ueno,et al. Dendritic cell subsets in health and disease , 2007, Immunological reviews.
[257] C. Figdor,et al. Identification of DC-SIGN, a Novel Dendritic Cell–Specific ICAM-3 Receptor that Supports Primary Immune Responses , 2000, Cell.
[258] C. Geisler,et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes , 2007, Immunology.
[259] Wijaya Martanto,et al. Mechanism of fluid infusion during microneedle insertion and retraction. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[260] P. Matzinger. The Danger Model: A Renewed Sense of Self , 2002, Science.
[261] Lawrence Steinman,et al. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.
[262] D. Gebauer,et al. Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier. , 2003, Biophysical journal.
[263] Vincent J. Sullivan,et al. Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine , 2006, Infection and Immunity.
[264] I. Frazer,et al. Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model , 2010, PloS one.
[265] S. Halperin,et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.
[266] C. Alving,et al. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants , 2000, Infection and Immunity.